Combining pembrolizumab with chemotherapy for relapsed Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to evaluate the effectiveness and safety of pembrolizumab, an anti-PD-1 antibody, in combination with established chemotherapy regimens (ICE or DHAP) for patients with first-relapsed or refractory classical Hodgkin lymphoma. The study seeks to leverage the synergistic effects of checkpoint inhibition alongside conventional chemotherapy to create a more effective treatment option with reduced toxicity. By potentially replacing high-dose chemotherapy, this approach could improve patient outcomes and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed first relapse of cHL or primary refractory cHL

Exclusion Criteria:

* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma

Where it's running

• 1st Department of Medicine, Cologne University Hospital
  Cologne, Germany Recruiting

Study contacts

• Principal investigator: Andreas Engert, Prof. — 1st Department of Medicine, Cologne Universit Hospital
• Study coordinator: Michael Fuchs
• Email: ghsg@uk-koeln.de
• Phone: +49221478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining pembrolizumab and bendamustine for treating relapsed Hodgkin lymphoma

  This study is testing whether combining two drugs, pembrolizumab and bendamustine, can help people with relapsed Hodgkin lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT04510636

• Treatment of advanced solid tumors and lymphomas in children using pembrolizumab

  This study is testing if a new immunotherapy drug called pembrolizumab can help shrink or eliminate advanced solid tumors and lymphomas in children aged 12 to 18 who haven't responded to other treatments.

  Recruiting at 16 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 15 other locations · NCT02332668

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.